Mbiomics Secures $32.4M Series A Funding Backed by MIG Fonds and Bayern Kapital

Why It Matters

The infusion of €30 million accelerates Mbiomics’ transition to clinical trials, positioning it at the forefront of microbiome‑based cancer therapies and signaling strong investor confidence in European tech‑bio innovation.

Key Takeaways

• Mbiomics secured €30M (~$33M) Series A funding.
• Funding backs MBX-116, a microbiome therapy for melanoma.
• AI-driven platform designs and scales complex microbial consortia.
• MIG Fonds and Bayern Kapital led the oversubscribed round.
• Company plans Phase 1b trial in 2027, expanding pipeline.

Pulse Analysis

The European tech‑bio sector is gaining momentum as venture capital flows into niche areas like synthetic microbiome therapeutics. Mbiomics’ €30 million raise, backed by prominent German investors, underscores a broader trend where funds are allocated to companies that can bridge the gap between academic microbiome research and commercial drug development. By securing capital at a valuation that reflects both scientific promise and market potential, Mbiomics joins a select group of startups poised to redefine how gut‑derived interventions are manufactured and regulated.

At the core of Mbiomics’ strategy is an AI‑enhanced platform that integrates high‑resolution profiling, large‑scale co‑cultivation, and patient stratification. This technology stack enables the design of precise microbial consortia, moving beyond traditional fecal transplants toward reproducible, pharma‑grade live biotherapeutic products (LBPs). The lead candidate, MBX‑116, aims to augment immune checkpoint inhibitors by priming the gut microbiome, a mechanism supported by emerging clinical data linking microbiota composition to cancer immunotherapy response. The planned Phase 1b trial in 2027 will provide critical safety and efficacy data, potentially opening a new therapeutic class.

The funding round also signals confidence in Europe’s ability to nurture high‑impact biotech ventures. With a GMP‑compliant facility already in place, Mbiomics can accelerate its pipeline beyond oncology into autoimmune and neurodegenerative indications, leveraging the gut‑brain and gut‑immune axes. As regulatory frameworks evolve to accommodate LBPs, early movers like Mbiomics stand to capture significant market share, attracting further investment and partnership opportunities from pharmaceutical giants seeking to integrate microbiome science into their portfolios.

Deal Summary

Mbiomics GmbH, a Munich‑based biotech startup, announced the final closing of its Series A round, raising a total of €30 million (≈$32.4 million) from existing investors MIG Fonds and Bayern Kapital. The funding will enable the company to transition from platform development to clinical execution of its live biotherapeutic product MBX‑116 for cancer immunotherapy. The round highlights growing investor interest in AI‑driven microbiome therapeutics.